A strategy for targeting gene therapy against cancer mediated by epidermal growth factor receptor.
- Author:
Hua-Sheng FANG
1
;
Mei HONG
;
Shu-Zheng ZHANG
;
Sheng-Dong LU
Author Information
- Publication Type:Journal Article
- MeSH: ADP Ribose Transferases; genetics; pharmacology; Bacterial Toxins; genetics; pharmacology; Base Sequence; Cell Line, Tumor; Cells; DNA; genetics; Exotoxins; genetics; pharmacology; Gene Targeting; Genetic Therapy; Genetic Vectors; Histones; genetics; Humans; Molecular Sequence Data; Receptor, Epidermal Growth Factor; genetics; metabolism; Recombinant Fusion Proteins; genetics; metabolism; pharmacology; Transfection; Virulence Factors; genetics; pharmacology
- From: Acta Academiae Medicinae Sinicae 2004;26(6):661-665
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish a protocol for the targeting gene therapy against cancer with rich epidermal growth factor receptor (EGFR).
METHODSA recombinant pcDNA3.1-PE III mut was constructed and combined with a non-viral vector, a fusion protein histone H1, epidermal growth factor C-loop previously expressed by us, to be a protein-DNA complex in vitro. Using the complex to treat BT-325 and Hela cancer cells with EGFR and JK cells without EGFR. The killing rates of the cells was calculated after 48 h of incubation at 37 degrees C.
RESULTSTo BT-325 and Hela cells, the killing rates were 46.03% and 48.12% respectively. To JK cells, the complex had no killing function.
CONCLUSIONThe protocol for targeting gene therapy against cancer with EGFR has been established successfully.
